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Aims:Monosodiumglutamate (MSG) is a neuroexcitatory amino acid used in human food to enhance ﬂavor.MSG
can affect the morphological and electrophysiological organization of the brain. This effect is more severe during
brain development. Here, we investigated the electrophysiological and morphological effects of MSG in the de-
veloping rat brain by characterizing changes in the excitability-related phenomenon of cortical spreading depres-
sion (CSD) and microglial reaction.
Main methods: From postnatal days 1–14, Wistar rat pups received 2 or 4 g/kg MSG (groups MSG-2 and MSG-4,
respectively; n = 9 in each group), saline (n = 10) or no treatment (naïve group; n = 5) every other day. At
45–60 days, CSD was recorded on two cortical points for 4 h. The CSD parameters velocity, and amplitude and
duration of the negative potential changewere calculated. Fixative-perfused brain sectionswere immunolabeled
with anti-IBA-1 antibodies to identify and quantify cortical microglia.
Key ﬁndings: MSG-4 rats presented signiﬁcantly higher velocities (4.59 ± 0.34 mm/min) than the controls
(saline, 3.84 ± 0.20 mm/min; naïve, 3.71 ± 0.8 mm/min) and MSG-2 group (3.75 ± 0.10 mm/min). The am-
plitude (8.8 ± 2.2 to 11.2 ± 1.9 mV) and duration (58.2 ± 7.1 to 73.6 ± 6.0 s) of the negative slow potential
shift was similar in all groups. MSG-treatment dose-dependently increased the microglial immunolabeling.
Signiﬁcance: The results demonstrate a novel, dose-dependent action of MSG in the developing brain, character-
ized by acceleration of CSD and signiﬁcantmicroglial reaction in the cerebral cortex. The CSD effect indicates that
MSG can inﬂuence cortical excitability, during brain development, as evaluated by CSD acceleration. Data suggest
caution when consuming MSG, especially in developing organisms.© 2013 Elsevier Inc. All rights reserved.Introduction
The increased incidence of obesity inmodern society appears to be a
consequence of the association between organic factors (genetic and
hormonal predisposition) and several exogenous factors, including
overconsumption of a fat-rich diet and a sedentary lifestyle, facilitated
by the excessive use ofmodern electronicmedia that reduce daily phys-
ical activity, such as remote controls and electronic games. The fact that
the incidence of obesity is also increasing in childhood is of great con-
cern (Dachs, 2007).
In the last decade, a new and challenging hypothesis has linked obe-
sity, hyperphagia and growth hormone (GH) deﬁciency to the con-
sumption of elevated amounts of the amino acid glutamate (GLU)
(Hermanussen and Tresguerres, 2003a,b). Supraphysiological doses of
GLU are toxic to neuronal cells (Hermanussen and Tresguerres, 2005).rsidade Federal de Pernambuco,
1 21268473.
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ghts reserved.A broadly used model for studying this issue in experimental animals
consists of treating the animals with repeated subcutaneous adminis-
tration of monosodium glutamate (MSG). MSG is a neuroexcitatory
amino acid used as a ﬂavoring agent; it can be harmful to the central
nervous system if consumed in great amounts (Nemeroff et al., 1978).
Brain lesions and obesity have been reported in adultmice andmonkeys
previously treated with MSG early in life (Abraham et al., 1971).
During nervous system development, the activation of glutamate re-
ceptorsmay play important roles in naturally occurring neuron death as
well as various neurodegenerative disorders. Over-activation of the glu-
tamate ionotropic receptors leads to excitotoxic cell death and can in-
duce apoptosis or necrosis depending on the intensity of receptor
activation (Johnston, 2005). These alterations likely inﬂuence electrical
activity in the brain (Sadeghian et al., 2012). Therefore, we investigated
the effect of previous treatment with MSG on the electrophysiological
phenomenon known as “cortical spreading depression” (CSD) in the
brains of weaned young rats.
CSD has been characterized electrophysiologically in laboratory ani-
mals (Leão, 1944, 1947) and humans (Dohmen et al., 2008; Fabricius
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mals, CSD can be produced by electrical, mechanical or chemical stimu-
lation of one point of the tissue and then spread concentrically to
remote cortical regions (Leão, 1944; Gorji, 2001). This response propa-
gates slowly as a “wave” of reduced cortical electrical activity. The neu-
ral tissue normally offers resistance to CSD propagation. This resistance
can be increased or decreased by experimentalmanipulations, resulting
in lower or higher propagation velocity, respectively (Guedes, 2011;
Rocha-de-Melo et al., 2006). Measuring the velocity of CSD propagation
along the cortical tissue is a reasonable and simple method for estimat-
ing susceptibility of the brain to CSD under clinically relevant conditions
known to inﬂuence brain excitability (Amaral et al., 2009). Experimen-
tal conditions that facilitate or impair the brain's ability to produce
and propagate CSDmay be helpful to understanding the electrophys-
iological processes dependent on brain excitability and related diseases,
such as epilepsy (Leão, 1944, 1972; Guedes and Cavalheiro, 1997;
Guedes et al., 2009).
The present study aimed to investigate possible electrophysiological
changes in the developing brain, caused by treatment with MSG, as in-
dicated byCSDpropagation in rats.Wepostulated that the susceptibility
of the brain to CSD would be altered in weaned young rats that are
treated early in life with MSG. In addition, we examined how early
administration of MSG affects microglial cells by analyzing IBA1-
immunolabeled cells in the motor area of the cerebral cortex.
Materials and methods
Animals
Male Wistar rat pups received 2 g/kg or 4 g/kg MSG (MSG-2 and
MSG-4, respectively; n = 9 for each group) subcutaneously every
other day during the ﬁrst 14 days of life. The groups were compared
to two control groups: one injected with saline (group Sal; n = 10)
and one that did not receive any injection (naïve group; n = 5). After
weaning, the pups were housed in polypropylene cages (51 cm ×
35.5 cm × 18.5 cm; 3–4 per cage) in a room maintained at 22 ± 1 °C
with a 12:12-h light–dark cycle (lights on at 7 a.m.) and fed a lab
chow diet with 23% protein (Purina do Brazil Ltd.). The animals were
handled in accordance with the norms of the Ethics Committee for
Animal Research of the Universidade Federal de Pernambuco, Brazil,
which complies with the “Principles of Laboratory Animal Care”
(National Institutes of Health, Bethesda, USA).
Body weight
Body weight was measured on postnatal days 2, 10 and 45–50.
CSD recording
When the animals were 45 to 60 days old, they were submitted to
CSD recording for a 4-h period. Under anesthesia (1 g/kg urethane
plus 40 mg/kg chloralose, ip), the rat's headwas secured in a stereotaxic
apparatus (Kopf, USA) and three trephine holes (2–3 mm in diameter)
drilled on the right side of the skull (two at the parietal bone and one at
the frontal bone). The three holes were aligned in the anteroposterior
direction and parallel to the midline.
CSD was elicited at 20 min intervals by applying a cotton ball
(1–2 mm diameter) soaked in 2% KCl solution (approximately
0.27 M) to the anterior hole drilled at the frontal region for 1 min. The
electrocorticogram (ECoG) and slow direct current (DC) potential
change accompanying CSD were recorded simultaneously at the two
parietal points on the cortical surface using a pair of Ag-AgCl agar-
Ringer electrodes. The electrodes consisted of plastic conic pipettes
(5 cm length, 0.5 mm tip inner diameter) ﬁlled with Ringer solution
and solidiﬁed with the addition of 0.5% agar, into which a chlorided
silver wire was inserted. The pipettes were ﬁxed in pairs withcyanoacrylate glue so that the interelectrode distance was constant for
each pair (4–5.5 mm). Each pair of electrodeswasﬁxed to the electrode
holder of the stereotaxic apparatus so that the recording electrodes
could be placed gently on the intact dura-mater under the guidance of
a low-powermicroscope without any excessive pressure on the cortical
surface. A common reference electrode of the same type was placed
on the nasal bones. The velocity of CSD propagation was calculated
based on the time required for a CSD wave to cross the distance
between the two recording electrodes. The initial point of each negative
rising phase was used as the reference point for the measurement of
CSD velocities. During the recording session, rectal temperature was
maintained at 37 ± 1 °C by a heating blanket. After the recording ses-
sion was terminated, the anesthetized animal was submitted to eutha-
nasia by bulbar injury, which was carried out by introducing a sharp
needle into the cisterna magna, provoking immediate cardiorespiratory
arrest.
Duration and amplitude of slow potential shifts
For all CSD episodes, we calculated the amplitude and duration of
the negative slow potential shifts of the CSD waves recorded in the
two cortical points: 1 and 2 (see inset in Fig. 2).
Analysis of immunolabeled microglial cells
An additional group of 12 rats treated with saline (n = 4), MSG-2
(n = 3) and MSG-4 (n = 5) were perfused with 0.9% saline solution
followed by 4% paraformaldehyde diluted in 0.1 M phosphate-
buffered saline, pH 7.4. The brains were removed and immersed in the
ﬁxative during 4 h and thereafter transferred to a 30% (w/v) sucrose
for cryoprotection. Longitudinal serial sections (40-μm thickness)
were obtained at −20 °C with a cryoslicer (Leica 1850). Sections
were immunolabeled with a polyclonal antibody against the ionized
calcium-binding adapter molecule 1 (IBA-1) to detect microglia (anti-
IBA-1, #019-19741; Wako Pure Chemical Industries Ltd., Osaka,
Japan). All chemicals used in this investigation were supplied by Vector
Labs (Burlingame, CA, USA) or Sigma–Aldrich (Poole, UK). Free-ﬂoating
sections were submitted to endogenous peroxidase blocking (2% H2O2
in 70% methanol for 10 min); then sections were incubated for 1 h in
blocking buffer solution (BB) containing 0.05 M Tris-buffered saline
(TBS) pH 7.4, 10% fetal calf serum, 3% bovine serum albumin and 1%
Triton X-100. Afterwards, sections were incubated overnight at 4 °C
with rabbit anti-Iba-1 (1:1,500 diluted in BB solution). After washes
with TBS + 1% Triton, sections were incubated at room temperature
for 1 h with biotinylated anti-rabbit (1:500) secondary antibodies.
Sections were then rinsed in TBS + 1% Triton and incubated with
horseradish peroxidase streptavidin (1:500). The peroxidase reaction
was visualized by incubating the sections in Tris buffer containing
0.5 mg/ml 3, 3′-diaminobenzidine (DAB) and 0.33 μl/ml H2O2. Finally,
sections weremounted, dehydrated in graded alcohols and after xylene
treatment coverslipped in Entellan®. For each animal, densitometric
analysis was performed on four parallel longitudinal sections. In each
section, we analyzed photomicrographs of four ﬁelds within the
motor cortex (layer 5) using the software Image J. A Leica DMLSmicro-
scope coupled to SAMSUNG high level color camera (model SHC-
410NAD) was used to obtain digital images from brain sections. Images
from the motor cortex immunoreacted for Iba1 were obtained with a
20× microscope objective. Care was taken to obtain the digital images
using the same light intensity conditions. We analyzed the area occu-
pied by the Iba1-labeled cells aswell as the immunoreactivity expressed
as arbitrary units.
Statistical analysis
Intergroup differences were compared by ANOVA, followed by a
post hoc (Tukey–Kramer) test when indicated. Statistical analyses
Fig. 2. (A) Diagram of the rat skull showing the location of KCl application, the reference
electrode and the recording points 1 and 2 (at which the traces in B to D marked with the
same numbers were recorded). (B–D) Electrocorticogram (E) and slow potential change
(P) recorded during cortical spreading depression (CSD) in three 45- to 50-day-old rats
from the untreated group (Nv), saline (Sal) group and group treated with 4 g/kg
monosodium glutamate (MSG-4). The horizontal bars in P1 show the period (1 min)
of stimulation with 2% KCl necessary to elicit CSD. The vertical bars equal −10 mV and
−1 mV, respectively, for P and E (negativity is upwards).
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sidered signiﬁcant when P ≤ 0.05.
Results
Body weight
As illustrated in Fig. 1, MSG treatment was associated with a dose-
dependent reduction in body weight at 45–50 days of age. The differ-
ence was signiﬁcant (P b 0.05) in the group treated with the higher
MSG dose (MSG-4) compared to the control rats.
Velocity of CSD propagation
Fig. 2 shows representative electrophysiological recordings (slowDC
potential change and ECoG) in one MSG 4, one Sal and one naïve rat. In
all groups, 1-min stimulationwith 2% KCl at one point of the frontal cor-
tex elicited a single CSDwave that propagatedwithout interruption and
was recorded by the two electrodes located more posterior on the sur-
face of the parietal cortex (see stimulation and recording points in the
inset of Fig. 2). In each recording point, the ECoG depression and slow
potential change conﬁrmed the presence of CSD after KCl application.
As a rule, the recovery of the electrophysiological changes caused by
CSD took approximately 5 to 10 min, and we maintained a 20-min in-
terval between subsequent stimulations with KCl.
Fig. 3 presents the CSD propagation velocities calculated for all
groups. Treatmentwith 4 g/kgMSG early in life resulted in signiﬁcantly
higher CSD velocities (4.59 ± 0.34 mm/min) compared to the two con-
trol groups (saline: 3.84 ± 0.20 mm/min; naïve: 3.71 ± 0.8 mm/min).
The MSG-2 group had a mean velocity of 3.75 ± 0.10 mm/min.
Duration and amplitude of CSD waves
The amplitude and duration of the negative slow potential wave,
which is the hallmark of CSD, were measured at the two recording
points (point 1 and point 2). ANOVA revealed no signiﬁcant intergroup
difference. The mean amplitudes (in mV) for the controls, MSG-2 and
MSG-4 groups were, respectively, 8.8 ± 2.2, 9.0 ± 3.8 and 10.7 ± 3.0
for point 1, and 11.1 ± 3.9, 10.0 ± 1.5 and 11.2 ± 1.9 for point 2.
The durations (in s) for the controls, MSG-2 andMSG-4 groupswere re-
spectively 62.6 ± 10.3, 58.6 ± 7.7 and 58.2 ± 7.1 for point 1, and
73.6 ± 6.0, 63.6 ± 10.4 and 68.8 ± 7.6 for point 2. Data are presented
in Table 1.
Iba1 immunohistochemistry and densitometric analysis
The speciﬁc immunolabeling of the calcium-binding protein Iba1 in
the microglial cells enables the analysis of microglial distribution in
the cerebral cortexwithout the interference of the cortical blood vesselsFig. 1.Bodyweights of rats at 2, 10 and45–50 days of life. Sal, saline;Nv, naïve, or no treat-
ment; MSG-2, 2 g/kg subcutaneous MSG; MSG-4, 4 g/kg subcutaneous MSG. *P b 0.05
compared to control, ANOVA plus Tukey test. Data are presented as mean ± SEM. Groups
Sal and Nv were pooled, as their weights were similar.(Fig. 4A). Compared to the controls, MSG-treated animals presented
higher percentage of labeled area (Fig. 4B), and a higher immunoreac-
tivity as expressed in arbitrary units (Fig. 4C). This MSG effect was di-
rectly dependent on the MSG dose, with the highest effect seen in the
MSG-4 group.
Discussion
Our data suggested that the neural effects of MSG treatment early in
life are important determinants of body weight and documented elec-
trophysiological and microglial alterations in the cerebral cortex. The
body weight changes associated with MSG treatment conﬁrmed previ-
ous ﬁndings (Sun et al., 1991; Zhang et al., 1994; Lobato et al., 2011).
Electrophysiologically, we characterized a novel effect ofMSG in the de-
veloping rat brain.
Our main ﬁnding was that 4 g/kg, but not 2 g/kg, MSG treatment
early in life increased the brain's ability to propagate CSD when the an-
imals reached 45–60 days of age, as indicated by higher CSD velocities
compared to the velocities of the controls. As MSG treatment occurred
early in life and CSD acceleration, as well as the microglial reaction
was observed after weaning, we postulate that these effects of MSG
are permanent, or at least long lasting. In neonatal rats, MSG can causeFig. 3. Velocities of CSD propagation in 45- to 60-day-old rats that received previous
(during the lactation period) saline (Sal), no treatment (naïve group; Nv) or 2 g/kg and
4 g/kg MSG (subcutaneous injections; MSG-2 and MSG-4, respectively). Data are
presented as mean ± SEM of 12 CSD episodes elicited at 20-min intervals by 1-min KCl
application during the 4-h recording period. *P b 0.05 compared to the other groups,
ANOVA plus Tukey test.
Table 1
Amplitude and duration of the negative slow potential shifts of cortical spreading depres-
sion in rats treated with MSG.
CSD amplitude (mV) CSD duration (s)
Groups Point 1 Point 2 Point 1 Point 2
Saline + naïve (n = 10) 8.8 ± 2.2 11.1 ± 3.9 62.6 ± 10.3 73.6 ± 6.0
MSG-2 (n = 8) 9.0 ± 3.8 10.0 ± 1.5 58.6 ± 7.7 63.6 ± 10.4
MSG-4 (n = 7) 10.7 ± 3.0 11.2 ± 1.9 58.2 ± 7.1 68.8 ± 7.6
MSG-2, 2 g/kg; MSG-4, 4 g/kg. The treatment groups were compared to control groups
treated with saline or no treatment (naïve). The two control groups were pooled, as
they did not differ. Data are expressed as mean ± standard deviation. No signiﬁcant
differences were observed.
391C.B. Lima et al. / Life Sciences 93 (2013) 388–392structural, neuroendocrine and biochemical abnormalities (Zhang et al.,
1994; Olney, 1969; Beas-Zarate et al., 2001; Gonzalez-Burgos et al.,
2001), which raises the question of whether the MSG-induced electro-
physiological changes are caused by an MSG-induced brain lesion or
the expression of compensatory mechanisms against such lesion, as
previously suggested (Ureña-Guerrero et al., 2003).
The central nervous system is an important target organ for the ac-
tions of MSG, particularly during brain development. Brain maturation
in the rat occurs mainly during the lactation period, a stage in which
synaptogenesis is intense, corresponding to the synaptogenic period
in the human brain, approximately the ﬁrst year of life (Dobbing,
1968; Morgane et al., 1978). The relevance of our data for human
brain function is based on the fact that a growing part of the human
population consumes MSG as a food ﬂavoring, including children. In
European and Asian countries, the increasing consumption of MSG is a
matter of great concern (Beyreuther et al., 2007), not only due to the in-
creased risk of obesity but also due to the neurotoxic effects that can
occur with high consumption of MSG.
The glutamatergic system has been shown to be involved in the reg-
ulation of brain excitability in both humans (Stagg et al., 2011) and
laboratory animals (El-Hassar et al., 2011). Interestingly, Lopez-Perez
et al. (2010) recently demonstrated that MSG-treated rat pups have
altered EEG and behavioral reactions, suggesting seizure initiation.
In line with this evidence, we observed facilitation of CSD propagation
in the group treated with 4 g/kg MSG. This is important to the present
discussion because of the postulated relationship between CSD and
excitability-related neurological disorders like epilepsy (Guedes et al.,
1988; Guedes and Cavalheiro, 1997) and migraine (Vecchia and
Pietrobon, 2012).
Themechanisms bywhichMSG exerts its actions on the nervous sys-
tem are not yet fully clariﬁed. Hermanussen and Tresguerres (2005)Fig. 4. (A) Digital images of Iba1-immunolabeled microglial cells in longitudinal sections
through the motor cortex of three rats treated respectively with saline, 2 g/kg MSG and
4 g/kgMSG.Note the darker labeling in theMSG-4 group. Scale bars = 20 μm. (B) Percent
area occupied by the Iba1-labeled cells. (C) Immunoreactivity expressed as arbitrary units
(a.u.). Data are expressed as means ± standard deviations. *P b 0.05 compared to the sa-
line group. **P b 0.05 compared to the Saline and MSG-2 groups.showed increases in GLU levels and the activation of GLU receptors
after neonatal administration of 4 mgMSG/g body weight. They also re-
ported important changes in NMDA-Rmolecular compositionwith signs
of neuronal damage and an increase in glial cell reactivity. This last effect
is in line with our immunohistochemical data that showed increased
microglial reaction in the cerebral cortex. It is interesting to note that
Iba1-positive microglial cells have been shown to increase in the hippo-
campus under stressful conditions such as restraint (Park et al., 2011)
and aging (Viana et al., 2013).
On the other hand, Kaufhold et al. (2002) were able to prevent the
adverse effects of neonatal MSG treatment with concurrent administra-
tion of a selective and highly potent noncompetitive NMDA-R antago-
nist, dizocilpine maleate. In general, MSG has been demonstrated to
modulate brain excitability (Lopez-Perez et al., 2010), a process that
could inﬂuence phenomena such as seizures and CSD (Guedes and
Cavalheiro, 1997). Effects on neurotoxicity via the p38 pathway (Torres
et al., 2006) or increasing brain glutamate levels after MSG treatment
(Lopez-Perez et al., 2010) have been discussed but still require corrobo-
ration based on robust experimental evidence. However, one cannot ex-
clude the possibility that MSG administration during the postnatal
critical period of brain development could also inﬂuence other neuro-
transmitter systems, e.g., the GABAergic system (Ureña-Guerrero et al.,
2003, 2009). Furthermore, during development, glutamate may also
exert a neurotrophic function, positively inﬂuencing neuronal differenti-
ation and circuitry formation (McDonald and Johnston, 1990). This can
be relevant for excitability-related phenomena such as CSD.
Although the mechanisms by which MSG accelerates CSD propaga-
tion are not yet known, we can speculate based on CSD experiments in-
volving mechanisms that are also proposed as being involved in neural
MSG actions. Interestingly, changes in the p38 pathway have been re-
ported in animals with seizures induced by the manipulation of the
glutamatergic system (Che et al., 2001). In addition, the accumulation
of reactive oxygen species and subsequent release of nitric oxide
have been described as a consequence of glutamatergic stimulation
(Kostandy, 2012). Such neurotoxic effects seem to be counteracted by
the antioxidantmolecule ascorbic acid (Hashemet al., 2012), suggesting
that the antioxidants potentially exert neuroprotective actions against
MSG-induced oxidative stress (Farombi and Onyema, 2006). Notably,
all of these mechanisms are known to inﬂuence CSD, as demonstrated
previously by our laboratory (Guedes et al., 1988; Maia et al., 2009;
Monte-Guedes et al., 2011) and by others (Marrannes et al., 1988;
Viggiano et al., 2008).
In conclusion, we demonstrated for the ﬁrst time that the brains of
weaned rats treated with MSG during their development are more sus-
ceptible (or less resistant) to CSD propagation, without altering other
electrophysiological CSD parameters, particularly the amplitude and du-
ration of the negative DC potential typical of the phenomenon. The im-
munohistochemical data revealed that MSG also induced microglial
reaction in the cerebral cortex. We suggest that these MSG actions
are related to its excitability effects via synaptic glutamatergic transmis-
sion, which ultimately modulates brain excitability. Our ﬁndings stress
the importance of searching for the molecular mechanisms underlying
the actions of MSG in brain development and their electrophysiological
expression. As CSD is an energy-demanding phenomenon that involves
glutamate, ATP and glucose (Costa-Cruz et al., 2006), and its occurrence
involves neuron–glia interaction, we think that the present ﬁndings can
also be useful for further understanding the CSDunderlyingmechanisms.
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